Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02796105

Enrollment

232

Registered

2016-06-10

Start date

2016-06-30

Completion date

2017-07-10

Last updated

2017-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

Interventions

DRUGProgevera

DRUGOrgalutran

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Oocyte donors included in the oocyte donation program of Clinica EUGIN. * 1st oocyte donation cycle at Clínica EUGIN.

Exclusion criteria

* Polycistic Ovarian syndrome (PCOs). * Estradiol levels on day 2 of menstrual cycle \>70 pg/ml. * Hormone treatments up to 3 months before the oocyte donation cycle. * Medical contraindication to the treatments used in the study

Design outcomes

Primary

Measure	Time frame
donor ovarian response	1 month

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026